LFVN · LifeVantage Corporation

LifeVantage's third quarter fiscal 2026 results fell short of expectations, with revenue declining 25.2% year-over-year to $43.7 million. The primary driver was a sharp drop in sales of the MindBody GLP-1 System, which was only partially offset by contributions from the LoveBiome acquisition completed in October 2025. Revenue in the Americas region decreased 28.9%, while Asia/Pacific & Europe declined 7.7% (8.9% on a constant currency basis). Gross margin contracted to 79.0% from 81.0%, impacted by an inventory obsolescence allowance for the GLP-1 product and higher shipping costs. Operating income fell to $1.7 million from $4.1 million, and net income dropped to $1.4 million ($0.11 per diluted share) from $3.5 million ($0.26 per share). Adjusted EBITDA halved to $3.2 million. Management acknowledged the softer performance and is focused on cost management and strategic initiatives. The company declared a quarterly dividend of $0.05 per share, an 11.1% increase, and continued share repurchases with $59 million remaining under the buyback program. Guidance for fiscal 2026 revenue, adjusted EBITDA, and adjusted EPS was revised to the lower end of the previously issued range, reflecting ongoing headwinds. The company maintains a strong balance sheet with no debt and $12.5 million in cash.